1 Ocak 2022 Dergi makalesi Açık Erişim

Kalkanli Tas, Sevgi; Uzunoglu, Merve Saide; Uzunoglu, Aylin Seher; Kirkik, Duygu; Altunkanat, Derya; Kalkanli, Nevin

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 256005, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Univ Hlth Sci, Hamidiye Med Fac, Dept Immunol, Istanbul, Turkey", 
      "name": "Kalkanli Tas, Sevgi"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey", 
      "name": "Uzunoglu, Merve Saide"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Univ Hlth Sci, Hamidiye Inst Hlth Sci, Dept Immunol, Istanbul, Turkey", 
      "name": "Uzunoglu, Aylin Seher"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey", 
      "name": "Kirkik, Duygu"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Univ Hlth Sci, Hamidiye Med Fac, Dept Med Biol, Istanbul, Turkey", 
      "name": "Altunkanat, Derya"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Diyarlife Hosp, Dept Dermatol, Diyarbakir, Turkey", 
      "name": "Kalkanli, Nevin"
    }
  ], 
  "datePublished": "2022-01-01", 
  "description": "Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization, considering the previous usage of the technique for different infectious diseases.", 
  "headline": "Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19", 
  "identifier": 256005, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19", 
  "url": "https://aperta.ulakbim.gov.tr/record/256005"
}